Hypersensitivity to fluoroquinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone

Medicine (United States)

Volumn 95, Issue 23, 2016, Pages

  Fernandez, Tahia D ^a   Ariza, Adriana ^a   Palomares, Francisca ^a   Montanez, Maria I ^a   Salas, Maria ^b   Martin Serrano, Angela ^a   Fernandez, Ruben ^a   Ruiz, Arturo ^b   Blanca, Miguel ^b   Mayorga, Cristobalina ^a,b   Torres, Maria J ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Anaphylactic shock; Anaphylaxis; Basophils; Fluoroquinolones; Immediate hypersensitivity reactions

Indexed keywords

BIOLOGICAL MARKER; CD203C ANTIGEN; CD63 ANTIGEN; CHEMOKINE RECEPTOR CCR3; CIPROFLOXACIN; LYMPHOCYTE ANTIGEN; MOXIFLOXACIN; PLACEBO; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BASOPHIL; BASOPHIL ACTIVATION TEST; CELL ACTIVATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE FUNCTION TEST; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; URTICARIA; VERY ELDERLY; CHEMICALLY INDUCED; DRUG EFFECTS; FLOW CYTOMETRY; FOLLOW UP; HYPERSENSITIVITY, IMMEDIATE; IMMUNOLOGY; METABOLISM; PATHOLOGY; TIME FACTOR;

AGED; AGED, 80 AND OVER; BASOPHILS; BIOMARKERS; FEMALE; FLOW CYTOMETRY; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84975478407     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003679     Document Type: Article

References (42)

1. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Safety 2009;32:359-78.
2. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000;46 (suppl T1):17-24.
3. Dona I, Blanca-Lopez N, Torres MJ, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol 2012;22: 363-71.
4. Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Safety 2007;30:705-13.
5. Blanca-Lopez N, Andreu I, Torres Jaen MJ. Hypersensitivity reactions to quinolones. Curr Opin Allerg Clin Immunol 2011;11:285-91.
6. Lobera T, Audicana MT, Alarcon E, et al. Allergy to quinolones: low cross-reactivity to levofloxacin. J Investig Allergol Clin Immunol 2010;20:607-11.
7. Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004;113:155-60.
8. Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Safety 2006;29:1087.
9. Venturini Diaz M, Lobera Labairu T, del Pozo Gil MD, et al. In vivo diagnostic tests in adverse reactions to quinolones. J Investig Allergol Clin Immunol 2007;17:393-8.
10. Seitz CS, Brocker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. Clin Exp Allerg 2009;39:1738-45.
11. Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy 2011;66:247-54.
12. Blanca-Lopez N, Ariza A, Dona I, et al. Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clin Exp Allergy 2013;43:560-7.
13. Lapi F, Tuccori M, Motola D, et al. Safety profile of the fluoroquino-lones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Drug Safety 2010;33:789.
14. Gonzalez I, Lobera T, Blasco A, et al. Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. J Investig Allergol Clin Immunol 2005;15:146-9.
15. Sanchez-Morillas L, Rojas Perez-Ezquerra P, Reano-Martos M, et al. Systemic anaphylaxis caused by moxifloxacin. Allergol Immunopathol 2010;38:226-7.
16. Empedrad R, Darter AL, Earl HS, et al. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003;112:629-30.
17. Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Curr Allergy Asthma Rep 2005;5:15-21.
18. Ben Said B, Berard F, Bienvenu J, et al. Usefulness of basophil activation tests for the diagnosis of IgE-mediated allergy to quinolones. Allergy 2010;65:535-6.
19. Rouzaire P, Nosbaum A, Denis L, et al. Negativity of the basophil activation test in quinolone hypersensitivity: a breakthrough for provocation test decision-making. Int Arch Allergy Immunol 2012;157:299-302.
20. Sturm GJ, Kranzelbinder B, Sturm EM, et al. The basophil activation test in the diagnosis of allergy: technical issues and critical factors. Allergy 2009;64:1319-26.
21. Iqbal K, Bhargava K, Skov PS, et al. A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria. Clin Transl Allergy 2012;2:19.
22. Mayorga C, Andreu I, Aranda A, et al. Fluoroquinolone photo-degradation influences specific basophil activation. Int Arch Allergy Immunol 2013;160:377-82.
23. Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008;38:921-8.
24. Sudheer PS, Hall JE, Read GF, et al. Flow cytometric investigation of peri-anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia 2005;60:251-6.
25. De Week AL, Sanz ML, Gamboa PM, et al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. II. Technical issues. J Investig Allergol Clin Immunol 2008;18:143-55.
26. Erdmann SM, Sachs B, Kwiecien R, et al. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. Allergy 2004;59:1102-9.
27. Ghannadan M, Hauswirth AW, Schernthaner GH, et al. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol 2002;127:299-307.
28. Platz IJ, Binder M, Marxer A, et al. Hymenoptera-venom-induced upregulation of the basophil activation marker ecto-nucleotide pyro-phosphatase/phosphodiesterase 3 in sensitized individuals. Int Arch Allergy Immunol 2001;126:335-42.
29. Ocmant A, Peignois Y, Mulier S, et al. Flow cytometry for basophil activation markers: the measurement of CD203c up-regulation is as reliable as CD63 expression in the diagnosis of cat allergy. J Immunol Methods 2007;320:40-8.
30. MacGlashan D Jr. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy 2010;40:1365-77.
31. MacGlashan D Jr. Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils. Int Arch Allergy Immunol 2012;159:243-52.
32. Buhring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004;133:317-29.
33. MacGlashan DW Jr. Basophil activation testing. J Allergy Clin Immunol 2013;132:777-87.
34. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Networksymposium. J Allergy Clin Immunol 2006; 117:391-7.
35. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs-an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-12.
36. Gomez E, Campo P, Rondon C, et al. Role of the basophil activation test in the diagnosis of local allergic rhinitis. J Allergy Clin Immunol 2013;132:975-6. e1-5.
37. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015;519:237-41.
38. Sokol CL, Chu NQ, Yu S, et al. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol 2009;10:713-20.
39. Perrigoue JG, Saenz SA, Siracusa MC, et al. MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nature Immunol 2009;10:697-05.
40. Boumiza R, Monneret G, Forissier MF, et al. Marked improvement of the basophil activation test by detecting CD203c instead of CD63. Clin Exp Allergy 2003;33:259-65.
41. Fernandez TD, Torres MJ, Blanca-Lopez N, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009;64:242-8.
42. Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010;125:502. e2.